S
Michael Burke
Chief Commercial Officer, Ovation
SPECIALIZES IN: "Creative solutions" to product strategy
ROLE MODELS: "Can do good and do well at the same time"
Doing deals is fun," says Michael Burke, who's helped build Ovation from "a couple people in a room to 350 employees, 20 products, and four development programs." Executing CEO Jeff Aronin's strategy of acquiring and relaunching Big Pharma drugs in underserved market segments, Burke has become expert in prudent risk—the industry's holy grail.
Michael Burke
Training in what he calls creative solutions primed him for setting the commercial agenda at Ovation, where innovation barely describes the new forms of life he and Aronin have discovered in acquiring, partnering, and marketing their Big Pharma ugly ducklings. Burke has had the most fun with Sabril, which prior to Ovation sat at FDA "with an open Approvable Letter longer than any other product in history." But by collaborating with academics and advocates, Ovation filed a new NDA for infantile spasms, a condition with high unmet need.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.